P63: Preemptive Temporary Right Ventricular Assist Device Implantation For Severe Biventricular Heart Failure: A Case Series

Abstract

Purpose: We sought to investigate the clinical results of preemptive temporary right ventricular assist device (RVAD) placement with left ventricular assist device (LVAD) implantation for anticipated right ventricular failure. Methods: Patients at risk for right ventricular failure were identified by the heart team. After median sternotomy, Protec-duo (LivaNova, London, UK) dual-stage cannula was inserted from the right internal jugular vein under fluoroscopy guidance, and advanced into the pulmonary artery to the bifurcation of the main pulmonary artery. This was then connected to the venous drainage from the right atrium for cardio pulmonary bypass (CPB). After LVAD implantation, we connected the Protec-duo cannula to the RVAD with oxygenator, and weaned CPB (Figure). Results: A total of 11 patients have received BiVAD implantation with this technique. The median age of patients was 55 years [Interquartile range (IQR): 51 – 63.5] and all patients were male. 63.6 % (7/11) of the patients were INTERMACS profile 1 or 2. Preoperatively, the median pulmonary artery pulsatility index was 4.0 [1.5 – 4.9] and median right ventricular stroke work index was 454.1 g/m/beat/m2 [436.5 – 530.2]. Postoperatively, the oxygenators were removed on median postoperative day (POD) 3.5 [3 – 5]. Patients received mechanical ventilation for a median of 4 days [1.5 – 12] and RVADs were explanted on median POD 8 [7 – 19) with local anesthesia. Perioperative complications included delayed sternal closure [54.5% (6/11)], re-exploration for bleeding [18% (2/11)], acute kidney injury [36% (4/11)], and heparin induced thrombocytopenia [18% (2/11)]. 30-day mortality was 0% (0/11). Conclusion: Preemptive temporary RVAD implantation strategy for right heart failure post-LVAD showed acceptable clinical outcomes without any 30-day mortality.